Deadline Alert: Elevance Health, Inc. (ELV) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose adverse facts regarding its business operations and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Financial Performance - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, which led to a stock price drop of $32.21, or 5.8%, closing at $520.93 per share [2]. - On October 17, 2024, Elevance reported third quarter 2024 financial results, missing EPS consensus estimates by 13.7% and lowering its EPS guidance for 2024 by 11.3%, resulting in a further stock price decline of $52.61, or 10.6%, to close at $444.35 per share [3]. Lawsuit Details - The class action complaint alleges that Elevance's management made materially false and misleading statements and failed to disclose significant adverse facts, including the higher costs associated with sicker patients remaining on Medicaid and inadequate reflection of these costs in financial guidance [4]. - Investors who purchased Elevance common stock during the Class Period have until July 11, 2025, to file a lead plaintiff motion in the lawsuit [5].